Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain | 11 | 2023 | 305 | 2.070 |
Why?
|
| Spinal Cord | 12 | 2013 | 139 | 2.060 |
Why?
|
| Analgesics | 12 | 2023 | 127 | 2.000 |
Why?
|
| Neuralgia | 5 | 2020 | 49 | 1.790 |
Why?
|
| Microglia | 9 | 2014 | 58 | 1.670 |
Why?
|
| Cannabinoids | 6 | 2020 | 43 | 1.630 |
Why?
|
| Receptor, Cannabinoid, CB2 | 5 | 2012 | 17 | 1.460 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2022 | 51 | 1.460 |
Why?
|
| Macrophages | 5 | 2019 | 194 | 1.360 |
Why?
|
| Hyperalgesia | 7 | 2022 | 88 | 1.320 |
Why?
|
| Pain, Postoperative | 6 | 2022 | 178 | 1.210 |
Why?
|
| Cannabis | 3 | 2022 | 20 | 1.170 |
Why?
|
| Dual Specificity Phosphatase 6 | 4 | 2014 | 5 | 1.140 |
Why?
|
| Clonidine | 4 | 2007 | 62 | 1.070 |
Why?
|
| Animals | 36 | 2023 | 7694 | 1.040 |
Why?
|
| Rats | 21 | 2022 | 1675 | 0.940 |
Why?
|
| Keratinocytes | 2 | 2019 | 30 | 0.840 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 611 | 0.840 |
Why?
|
| Sciatic Neuropathy | 3 | 2007 | 15 | 0.840 |
Why?
|
| Cannabidiol | 1 | 2022 | 7 | 0.840 |
Why?
|
| Astrocytes | 2 | 2014 | 58 | 0.830 |
Why?
|
| Inflammation | 4 | 2019 | 542 | 0.810 |
Why?
|
| Fibroblasts | 2 | 2019 | 118 | 0.800 |
Why?
|
| Indoles | 5 | 2017 | 60 | 0.770 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 2 | 2012 | 4 | 0.770 |
Why?
|
| Skin | 4 | 2022 | 217 | 0.770 |
Why?
|
| Acetaminophen | 4 | 2007 | 20 | 0.740 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 22 | 0.730 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2022 | 756 | 0.720 |
Why?
|
| Cytokines | 6 | 2017 | 262 | 0.710 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 73 | 0.700 |
Why?
|
| Antigens, CD | 2 | 2019 | 105 | 0.700 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2013 | 37 | 0.670 |
Why?
|
| Tretinoin | 3 | 2006 | 34 | 0.650 |
Why?
|
| Dual Specificity Phosphatase 1 | 3 | 2012 | 29 | 0.600 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2006 | 42 | 0.600 |
Why?
|
| Calcium-Binding Proteins | 5 | 2010 | 45 | 0.590 |
Why?
|
| Nanotechnology | 1 | 2016 | 15 | 0.560 |
Why?
|
| Neuroglia | 4 | 2010 | 30 | 0.560 |
Why?
|
| Pain Measurement | 10 | 2010 | 370 | 0.550 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 35 | 0.550 |
Why?
|
| Behavior, Animal | 9 | 2012 | 262 | 0.530 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2010 | 41 | 0.520 |
Why?
|
| Rats, Wistar | 9 | 2007 | 83 | 0.520 |
Why?
|
| Pain Threshold | 5 | 2008 | 95 | 0.510 |
Why?
|
| Gene Expression | 1 | 2016 | 345 | 0.510 |
Why?
|
| Facility Design and Construction | 1 | 2014 | 1 | 0.500 |
Why?
|
| Animal Husbandry | 1 | 2014 | 7 | 0.500 |
Why?
|
| Zebrafish | 1 | 2014 | 23 | 0.500 |
Why?
|
| Housing, Animal | 1 | 2014 | 23 | 0.490 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 14 | 0.480 |
Why?
|
| Isoquinolines | 1 | 2013 | 7 | 0.450 |
Why?
|
| Touch | 2 | 2012 | 35 | 0.430 |
Why?
|
| Drug Tolerance | 3 | 2010 | 35 | 0.420 |
Why?
|
| Nitrates | 2 | 2007 | 27 | 0.420 |
Why?
|
| Osteoarthritis | 1 | 2013 | 78 | 0.420 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 502 | 0.420 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 1040 | 0.420 |
Why?
|
| Humans | 21 | 2023 | 32297 | 0.420 |
Why?
|
| Phosphorylation | 5 | 2014 | 234 | 0.410 |
Why?
|
| Anesthetics, Dissociative | 1 | 2011 | 4 | 0.400 |
Why?
|
| Ketamine | 1 | 2011 | 20 | 0.400 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 77 | 0.390 |
Why?
|
| Cell Movement | 2 | 2009 | 171 | 0.380 |
Why?
|
| Male | 22 | 2019 | 19488 | 0.380 |
Why?
|
| Endocannabinoids | 1 | 2010 | 35 | 0.360 |
Why?
|
| Reflex | 3 | 2007 | 16 | 0.340 |
Why?
|
| Sciatic Nerve | 2 | 2006 | 36 | 0.340 |
Why?
|
| Administration, Oral | 3 | 2006 | 185 | 0.330 |
Why?
|
| Oligodendroglia | 1 | 2008 | 3 | 0.320 |
Why?
|
| Depression | 1 | 2011 | 436 | 0.310 |
Why?
|
| Mice | 5 | 2022 | 2524 | 0.300 |
Why?
|
| Leukocytes | 3 | 2019 | 60 | 0.300 |
Why?
|
| Xanthines | 3 | 2011 | 7 | 0.300 |
Why?
|
| Lipopolysaccharides | 3 | 2017 | 110 | 0.290 |
Why?
|
| Microfilament Proteins | 5 | 2010 | 35 | 0.280 |
Why?
|
| Neuritis | 1 | 2005 | 4 | 0.270 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2005 | 33 | 0.260 |
Why?
|
| Physical Stimulation | 5 | 2006 | 84 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 213 | 0.240 |
Why?
|
| Paclitaxel | 2 | 2022 | 67 | 0.240 |
Why?
|
| Apoptosis | 1 | 2006 | 368 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 773 | 0.240 |
Why?
|
| Neuralgia, Postherpetic | 2 | 2015 | 6 | 0.230 |
Why?
|
| Inflammation Mediators | 2 | 2016 | 103 | 0.230 |
Why?
|
| Cell Line | 2 | 2016 | 462 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 77 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 675 | 0.220 |
Why?
|
| Interferon Type I | 1 | 2022 | 14 | 0.210 |
Why?
|
| Lysophospholipids | 1 | 2022 | 24 | 0.210 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 61 | 0.210 |
Why?
|
| California | 1 | 2022 | 64 | 0.210 |
Why?
|
| Rodentia | 1 | 2022 | 10 | 0.210 |
Why?
|
| Time Factors | 5 | 2017 | 2181 | 0.210 |
Why?
|
| Animals, Newborn | 2 | 2014 | 116 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 95 | 0.200 |
Why?
|
| Wound Healing | 2 | 2019 | 194 | 0.190 |
Why?
|
| United States | 3 | 2020 | 3983 | 0.180 |
Why?
|
| Back Pain | 1 | 2020 | 28 | 0.180 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2019 | 248 | 0.180 |
Why?
|
| Antibodies, Blocking | 1 | 2019 | 3 | 0.180 |
Why?
|
| Morphine | 2 | 2010 | 60 | 0.180 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.180 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.180 |
Why?
|
| Spinal Nerves | 2 | 2012 | 66 | 0.170 |
Why?
|
| Organ Culture Techniques | 1 | 2019 | 39 | 0.170 |
Why?
|
| Endoribonucleases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.170 |
Why?
|
| Cyclooxygenase 2 | 3 | 2019 | 46 | 0.170 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 48 | 0.170 |
Why?
|
| Dinoprostone | 1 | 2019 | 34 | 0.170 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2019 | 50 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2019 | 846 | 0.170 |
Why?
|
| Tachykinins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Administration, Cutaneous | 2 | 2017 | 117 | 0.160 |
Why?
|
| Sensory Receptor Cells | 1 | 2019 | 33 | 0.160 |
Why?
|
| Electric Stimulation | 3 | 2019 | 105 | 0.160 |
Why?
|
| RNA, Messenger | 2 | 2017 | 534 | 0.150 |
Why?
|
| Cyclohexanols | 2 | 2008 | 20 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2020 | 398 | 0.150 |
Why?
|
| Receptors, Opioid | 2 | 2023 | 38 | 0.140 |
Why?
|
| Genes, Reporter | 1 | 2016 | 40 | 0.140 |
Why?
|
| Neurons | 2 | 2013 | 413 | 0.140 |
Why?
|
| Zymosan | 2 | 2007 | 5 | 0.140 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 72 | 0.140 |
Why?
|
| Lumbar Vertebrae | 2 | 2019 | 98 | 0.140 |
Why?
|
| Transfection | 1 | 2016 | 202 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2010 | 470 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2016 | 50 | 0.130 |
Why?
|
| Receptors, Cannabinoid | 1 | 2015 | 26 | 0.130 |
Why?
|
| Diabetic Neuropathies | 1 | 2015 | 24 | 0.130 |
Why?
|
| Cyclooxygenase 1 | 2 | 2006 | 23 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2019 | 701 | 0.130 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 50 | 0.130 |
Why?
|
| Aquaculture | 1 | 2014 | 1 | 0.130 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2015 | 21 | 0.130 |
Why?
|
| Amines | 1 | 2015 | 22 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2006 | 305 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 75 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 122 | 0.120 |
Why?
|
| Substrate Specificity | 1 | 2014 | 90 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2016 | 468 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2015 | 406 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 37 | 0.120 |
Why?
|
| Arthritis, Experimental | 1 | 2003 | 5 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 44 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 61 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 759 | 0.110 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 262 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 137 | 0.110 |
Why?
|
| 4-Nitrophenylphosphatase | 1 | 2012 | 1 | 0.110 |
Why?
|
| Phenanthrenes | 1 | 2012 | 3 | 0.110 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 7 | 0.110 |
Why?
|
| Diterpenes | 1 | 2012 | 20 | 0.110 |
Why?
|
| Narcotics | 2 | 2010 | 19 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 117 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 915 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2008 | 57 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 238 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2011 | 157 | 0.090 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 56 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3358 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 85 | 0.080 |
Why?
|
| Hot Temperature | 2 | 2010 | 79 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2009 | 196 | 0.080 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 61 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2007 | 4 | 0.070 |
Why?
|
| Phenols | 1 | 2007 | 17 | 0.070 |
Why?
|
| Phenotype | 1 | 2009 | 656 | 0.070 |
Why?
|
| Anesthesia, Local | 1 | 2006 | 17 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2006 | 31 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 28 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 133 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2006 | 70 | 0.070 |
Why?
|
| Isoindoles | 1 | 2006 | 6 | 0.070 |
Why?
|
| Burns | 1 | 2007 | 102 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2006 | 27 | 0.070 |
Why?
|
| Ligation | 1 | 2006 | 60 | 0.070 |
Why?
|
| Injections | 1 | 2006 | 65 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2005 | 64 | 0.070 |
Why?
|
| Imidazoles | 1 | 2006 | 97 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 638 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2005 | 51 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 545 | 0.060 |
Why?
|
| Carrageenan | 1 | 2004 | 5 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 32 | 0.060 |
Why?
|
| Pressure | 1 | 2004 | 54 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 62 | 0.060 |
Why?
|
| Receptors, Opioid, mu | 1 | 2023 | 55 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 40 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2022 | 5 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2004 | 260 | 0.050 |
Why?
|
| Research | 1 | 2003 | 77 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2002 | 18 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 736 | 0.050 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 46 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 48 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 66 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 15 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 91 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2010 | 5 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 40 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 10 | 0.040 |
Why?
|
| Substance P | 1 | 2019 | 22 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 27 | 0.040 |
Why?
|
| TRPV Cation Channels | 1 | 2019 | 23 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 213 | 0.040 |
Why?
|
| Ganglia, Spinal | 1 | 2019 | 66 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 536 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 449 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 105 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 167 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2006 | 71 | 0.030 |
Why?
|
| Motor Neurons | 1 | 2006 | 56 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1522 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2015 | 5 | 0.030 |
Why?
|
| Ointments | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 64 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 140 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 2274 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 169 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 316 | 0.030 |
Why?
|
| Chloralose | 1 | 2003 | 1 | 0.030 |
Why?
|
| Female | 2 | 2022 | 20126 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 31 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 171 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 46 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 196 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 83 | 0.020 |
Why?
|
| Naloxone | 1 | 2010 | 28 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2010 | 59 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 220 | 0.020 |
Why?
|
| Morpholines | 1 | 2007 | 37 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2007 | 123 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 10398 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 11949 | 0.020 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 5 | 0.010 |
Why?
|
| Caffeine | 1 | 2003 | 32 | 0.010 |
Why?
|
| Steroids | 1 | 2003 | 38 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 77 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 301 | 0.010 |
Why?
|
Romero-Sandoval's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(247)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(51)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_